<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Freie B</submitter><funding>NHLBI NIH HHS</funding><funding>National Cancer Institute</funding><funding>NHGRI NIH HHS</funding><funding>NCI NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIH HHS</funding><funding>Office of Research Infrastructure Programs</funding><pagination>253-272</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11065175</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>38(5-6)</volume><pubmed_abstract>Oncogenic activation of MYC in cancers predominantly involves increased transcription rather than coding region mutations. However, MYC-dependent lymphomas frequently acquire point mutations in the MYC phosphodegron, including at threonine 58 (T58), where phosphorylation permits binding via the FBW7 ubiquitin ligase triggering MYC degradation. To understand how T58 phosphorylation functions in normal cell physiology, we introduced an alanine mutation at T58 (T58A) into the endogenous &lt;i>c-Myc&lt;/i> locus in the mouse germline. While MYC-T58A mice develop normally, lymphomas and myeloid leukemias emerge in ∼60% of adult homozygous T58A mice. We found that primitive hematopoietic progenitor cells from MYC-T58A mice exhibit aberrant self-renewal normally associated with hematopoietic stem cells</pubmed_abstract><journal>Genes &amp; development</journal><pubmed_title>A germline point mutation in the MYC-FBW7 phosphodegron initiates hematopoietic malignancies.</pubmed_title><pmcid>PMC11065175</pmcid><funding_grant_id>R35 CA231989</funding_grant_id><funding_grant_id>S10OD028685</funding_grant_id><funding_grant_id>DP2 HG012442</funding_grant_id><funding_grant_id>P01 HL084205</funding_grant_id><funding_grant_id>S10 OD028685</funding_grant_id><funding_grant_id>P01HL084205</funding_grant_id><funding_grant_id>DP2-HG012442</funding_grant_id><pubmed_authors>Carroll PA</pubmed_authors><pubmed_authors>Ramani V</pubmed_authors><pubmed_authors>Eisenman RN</pubmed_authors><pubmed_authors>Ramsey EL</pubmed_authors><pubmed_authors>Freie B</pubmed_authors><pubmed_authors>Varnum-Finney BJ</pubmed_authors><pubmed_authors>Bernstein I</pubmed_authors></additional><is_claimable>false</is_claimable><name>A germline point mutation in the MYC-FBW7 phosphodegron initiates hematopoietic malignancies.</name><description>Oncogenic activation of MYC in cancers predominantly involves increased transcription rather than coding region mutations. However, MYC-dependent lymphomas frequently acquire point mutations in the MYC phosphodegron, including at threonine 58 (T58), where phosphorylation permits binding via the FBW7 ubiquitin ligase triggering MYC degradation. To understand how T58 phosphorylation functions in normal cell physiology, we introduced an alanine mutation at T58 (T58A) into the endogenous &lt;i>c-Myc&lt;/i> locus in the mouse germline. While MYC-T58A mice develop normally, lymphomas and myeloid leukemias emerge in ∼60% of adult homozygous T58A mice. We found that primitive hematopoietic progenitor cells from MYC-T58A mice exhibit aberrant self-renewal normally associated with hematopoietic stem cells</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2026-06-05T22:37:19.775Z</modification><creation>2026-05-23T03:10:37.311Z</creation></dates><accession>S-EPMC11065175</accession><cross_references><pubmed>38565249</pubmed><doi>10.1101/gad.351292.123</doi></cross_references></HashMap>